Efficacy of Paclitaxel in Heavily Pretreated Small-Cell Lung Cancer Patients
Author Information
Author(s): EF Smit, E Fokkema, B Biesma, HJM Groen, W Snoek, PE Postmus
Primary Institution: University Hospital Groningen
Hypothesis
The study aims to evaluate the efficacy and toxicity of paclitaxel in patients with drug-resistant small-cell lung cancer.
Conclusion
Paclitaxel is active in drug-resistant small-cell lung cancer, showing a 29% partial response rate with manageable toxicity.
Supporting Evidence
- Of 24 patients, 7 had a partial response to treatment.
- The median survival time was 100 days.
- Life-threatening toxicity occurred in four patients, but most side effects were manageable.
- Paclitaxel was administered for a maximum of five cycles.
Takeaway
This study tested a cancer drug called paclitaxel on patients whose lung cancer didn't respond to other treatments, and it helped some of them feel better.
Methodology
Patients received paclitaxel 175 mg/m² intravenously every 3 weeks, with dose adjustments based on toxicity.
Potential Biases
Potential bias due to the lack of a control group and the open-label design.
Limitations
The study had a small sample size and included patients with varying degrees of prior treatment.
Participant Demographics
Median age was 56 years (range 39-73), with 83% male participants.
Statistical Information
Confidence Interval
95% CI 12-51%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website